Literature DB >> 18714309

Targeting of adenovirus vectors to the LRP receptor family with the high-affinity ligand RAP via combined genetic and chemical modification of the pIX capsomere.

Stéphanie Corjon1, Andreas Wortmann, Tatjana Engler, Nico van Rooijen, Stefan Kochanek, Florian Kreppel.   

Abstract

Adenovirus (Ad) vector targeting requires presentation of specific ligands on the virion's surface. Geneti-chemical targeting is based on the genetic introduction of cysteine residues bearing reactive thiol groups into solvent-accessible capsomeres of the virion and subsequent chemical coupling of ligands. Here, we exploited this technology to modify the pIX capsomere with high-affinity ligands. Genetic introduction of C-terminal cysteines to pIX allowed for specific coupling of full-length proteins to the virion, while not affecting vector production. Direct comparison of the two high-affinity ligands receptor- associated protein (RAP) and transferrin (Tf) revealed that targeting after coupling of a high-affinity ligand to pIX presumably requires release of the ligand from its receptor after cell entry. In addition, data obtained by live cell imaging of labeled vector particles demonstrated that coupling of very large proteins to pIX can impair intracellular vector particle trafficking. Finally, we demonstrate that the geneti-chemical targeting technology is suitable for in vivo targeting to liver after intravenous injection. Our data provide significant insight into basic requirements for successful targeting of pIX-modified Ad vectors.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18714309     DOI: 10.1038/mt.2008.174

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  14 in total

1.  Adenovirus with hexon Tat-protein transduction domain modification exhibits increased therapeutic effect in experimental neuroblastoma and neuroendocrine tumors.

Authors:  Di Yu; Chuan Jin; Justyna Leja; Nadim Majdalani; Berith Nilsson; Fredrik Eriksson; Magnus Essand
Journal:  J Virol       Date:  2011-09-28       Impact factor: 5.103

2.  Fusion of Large Polypeptides to Human Adenovirus Type 5 Capsid Protein IX Can Compromise Virion Stability and DNA Packaging Capacity.

Authors:  Kathy L Poulin; Emily R McFall; Grace Chan; Natacha B Provost; Carin Christou; Adam C Smith; Robin J Parks
Journal:  J Virol       Date:  2020-08-17       Impact factor: 5.103

3.  Encapsulation of adenovirus serotype 5 in anionic lecithin liposomes using a bead-based immunoprecipitation technique enhances transfection efficiency.

Authors:  Natalie Mendez; Vanessa Herrera; Lingzhi Zhang; Farah Hedjran; Ralph Feuer; Sarah L Blair; William C Trogler; Tony R Reid; Andrew C Kummel
Journal:  Biomaterials       Date:  2014-08-22       Impact factor: 12.479

4.  Combined Genetic and Chemical Capsid Modifications of Adenovirus-Based Gene Transfer Vectors for Shielding and Targeting.

Authors:  Franziska Jönsson; Claudia Hagedorn; Florian Kreppel
Journal:  J Vis Exp       Date:  2018-10-26       Impact factor: 1.355

Review 5.  Barriers to systemic application of virus-based vectors in gene therapy: lessons from adenovirus type 5.

Authors:  Franziska Jönsson; Florian Kreppel
Journal:  Virus Genes       Date:  2017-07-28       Impact factor: 2.332

6.  Modifications of adenovirus hexon allow for either hepatocyte detargeting or targeting with potential evasion from Kupffer cells.

Authors:  Jan-Michael Prill; Sigrid Espenlaub; Ulrike Samen; Tatjana Engler; Erika Schmidt; Francesco Vetrini; Amanda Rosewell; Nathan Grove; Donna Palmer; Philip Ng; Stefan Kochanek; Florian Kreppel
Journal:  Mol Ther       Date:  2010-10-19       Impact factor: 11.454

7.  Retargeting of adenovirus vectors through genetic fusion of a single-chain or single-domain antibody to capsid protein IX.

Authors:  Kathy L Poulin; Robert M Lanthier; Adam C Smith; Carin Christou; Milagros Risco Quiroz; Karen L Powell; Ryan W O'Meara; Rashmi Kothary; Ian A Lorimer; Robin J Parks
Journal:  J Virol       Date:  2010-07-14       Impact factor: 5.103

8.  Targeting of adenovirus serotype 5 pseudotyped with short fiber from serotype 41 to c-erbB2-positive cells using bispecific single-chain diabody.

Authors:  Elena A Kashentseva; Joanne T Douglas; Kurt R Zinn; David T Curiel; Igor P Dmitriev
Journal:  J Mol Biol       Date:  2009-03-13       Impact factor: 5.469

9.  Improved adenovirus type 5 vector-mediated transduction of resistant cells by piggybacking on coxsackie B-adenovirus receptor-pseudotyped baculovirus.

Authors:  Ophélia Granio; Marine Porcherot; Stéphanie Corjon; Kuntida Kitidee; Petra Henning; Assia Eljaafari; Andrea Cimarelli; Leif Lindholm; Pierre Miossec; Pierre Boulanger; Saw-See Hong
Journal:  J Virol       Date:  2009-04-08       Impact factor: 5.103

10.  Transcellular targeting of fiber- and hexon-modified adenovirus vectors across the brain microvascular endothelial cells in vitro.

Authors:  Johanna P Laakkonen; Tatjana Engler; Ignacio A Romero; Babette Weksler; Pierre-Olivier Couraud; Florian Kreppel; Stefan Kochanek
Journal:  PLoS One       Date:  2012-09-27       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.